Skip to main content

Advertisement

SpringerLink
Log in

Intravenous Immunoglobulin (IVIG) Treatment Exerts Antioxidant and Neuropreservatory Effects in Preclinical Models of Alzheimer’s Disease

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer’s disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious. Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo. Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD. We suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, neuroprotective and synapto-protecting agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Schneider LS, Lahiri DK. The perils of Alzheimer’s drug development. Curr Alzheimer Res. 2009;6(1):77–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Lahiri DK, Long, JM, Maloney B, Greig NH. Lessons from a BACE1 inhibitor trial: Off-site but not off base. Alzheimers Dement. 2014. doi:10.1016/j.jalz.2013.11.004.

  3. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, et al. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci. 2005;25(4):823–9.

    Article  CAS  PubMed  Google Scholar 

  4. Lahiri DK, Maloney B, Zawia NH. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol Psychiatry. 2009;14(11):992–1003. Nature Publishing Group.

    Article  CAS  PubMed  Google Scholar 

  5. Selkoe DJ. SnapShot: pathobiology of Alzheimer’s disease. Cell. 2013;154(2):468–468.e1.

    Article  CAS  PubMed  Google Scholar 

  6. Perez FP, Bose D, Maloney B, Nho K, Shah K, Lahiri DK. Late-onset Alzheimer’s disease (LOAD) heating up and foxed by several proteins: pathomolecular efects of the aging process. J Alzheimer Dis. 2014;40(1):1–17.

    CAS  Google Scholar 

  7. Alley GM, Bailey JA, Chen D, Ray B, Puli LK, Tanila H, et al. Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J Neurosci Res. 2010;88(1):143–54.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Bailey JA, Lahiri DK. A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer’s disease. J Neurochem. 2010;112(4):843–53.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Bailey JA, Ray B, Greig NH, Lahiri DK. Rivastigmine lowers Aβ and increases sAPPalpha levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. PLoS ONE. 2011;6(7):e21954.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Ray B, Chauhan NB, Lahiri DK. Oxidative insults to neurons and synapse are prevented by AGE and SAC treatment in the neuronal culture and APP-Tg mouse model. J Neurochem. 2011;117(3):388–402.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Farlow MR, Brosch JR. Immunotherapy for Alzheimer’s disease. Neurol Clin. 2013;31(3):869–78.

    Article  PubMed  Google Scholar 

  12. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects ofAbeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlledphase I trial. Lancet. 2008;372:216–23.

    Article  CAS  PubMed  Google Scholar 

  13. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73:2061–70.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553–62.

    Article  CAS  PubMed  Google Scholar 

  15. Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, et al. Intravenous immunoglobulins as atreatment for Alzheimer’s disease: rationale and current evidence. Drugs. 2010;70:513–28.

    Article  CAS  PubMed  Google Scholar 

  16. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study ofintravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2009;30:1728–36.

    Article  CAS  PubMed  Google Scholar 

  17. http://www.baxter.com/press_room/press_releases/2013/05_07_13_gap_study.html. Accessed 12/15/2013.

  18. Magga J, Puli L, Pihlaja R, et al. Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer’s disease. J Neuroinflammation. 2010;7:90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Puli L, Pomeshchik Y, Olas K, Malm T, Koistinaho J, Tanila H. Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease. J Neuroinflammation. 2012;9:105.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Counts S, Perez S, He B, Mufson E. Intravenous immunoglobulin reduces tau pathology and preserves neuroplastic gene expression in the 3xTg mouse model of Alzheimer’s disease. Current Alz Res. 2014; In press.

  21. Sudduth TL, Greenstein A, Wilcock DM. Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies. J Neurosci. 2013;33(23):9684–92.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Bailey JA, Ray B, Lahiri DK. Intravenous immunoglobulin (IVIG) protects neuronal viability and synaptic markers in cultured degenerating primary hippocampal neurons. Societ Neurosci Abst. 2012;852.04.

  23. Lahiri DK, Ray B. Effect of IVIG in preserving human primary neurons and protecting them against oxidative stress. Alzheimers Dement. 2013;9(4):800.

    Article  Google Scholar 

  24. Lahiri DK, Ray B. Intravenous Immunoglobulin (IVIG) treatment exerts a protective effect against oxidative insults in primary human neuronal mixed cultures. Curr Alzheimer Res. 2014; In press.

  25. Long JM, Ray B, Lahiri DK. MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients. J Biol Chem. 2012;28(37):31298–310.

    Article  Google Scholar 

  26. Counts SE, Che S, Ginsberg SD, Mufson EJ. Gender differences in neurotrophin and glutamate receptor expression in cholinergic nucleus basalis neurons during the progression of Alzheimer’s disease. J Chem Neuroanat. 2011;42:111–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Ginsberg SD, Alldred MJ, Counts SE, Cataldo AM, Neve RL, Jiang Y, et al. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer’s disease progression. Biol Psychiatry. 2010;68:885–93.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

We sincerely appreciate the grant support from the Alzheimer’s Association (Zenith award and IIRG; DKL), the NIH (DKL and SEC), Baxter Healthcare (DKL and SEC), and the St. Mary’s Foundation (SEC).

Author information

Authors and Affiliations

  1. Department of Translational Science and Molecular Medicine, Michigan State University, 333 Bostwick Ave NE, Grand Rapids, MI, 49503, USA

    Scott E. Counts

  2. Department of Family Medicine, Michigan State University, 333 Bostwick Ave NE, Grand Rapids, MI, 49503, USA

    Scott E. Counts

  3. Department of Psychiatry, Indiana University School of Medicine, 791 Union Drive, Indianapolis, IN, 46202, USA

    Balmiki Ray & Debomoy K. Lahiri

  4. Department of Molecular Genetics, Indiana University School of Medicine, 791 Union Drive, Indianapolis, IN, 46202, USA

    Balmiki Ray & Debomoy K. Lahiri

  5. Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, 60612, USA

    Elliott J. Mufson, Sylvia E. Perez & Bin He

  6. Institute of Psychiatric Research, Indiana University School of Medicine, 791 Union Drive, Indianapolis, IN, 46202, USA

    Debomoy K. Lahiri

Authors
  1. Scott E. Counts
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Balmiki Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elliott J. Mufson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sylvia E. Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bin He
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Debomoy K. Lahiri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Scott E. Counts.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Counts, S.E., Ray, B., Mufson, E.J. et al. Intravenous Immunoglobulin (IVIG) Treatment Exerts Antioxidant and Neuropreservatory Effects in Preclinical Models of Alzheimer’s Disease. J Clin Immunol 34 (Suppl 1), 80–85 (2014). https://doi.org/10.1007/s10875-014-0020-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-014-0020-9

Keywords

Search

Navigation